GPR6, a G protein-coupled receptor, is primarily expressed in the medium spiny neurons of the striatum, specifically within the striatopallidal pathway. This pathway is heavily impacted by the loss of ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. The finding contrasts with positive results from previous phase II studies ...

Tan, S., Hermann, B., and Borrelli, E. 2003. "Dopaminergic Mouse Mutants: Investigating the Roles of the Different Dopamine Receptor Subtypes and the Dopamine Transporters." The International Review ...

Karuna Therapeutics focuses on developing therapies that target muscarinic cholinergic receptors to treat psychosis and cognitive impairment in CNS disorders. The Company's lead asset, KarXT, has ...